AU2005300424A1 - Novel pharmaceutical compositions and the uses thereof for controlling the different forms of addiction to drugs - Google Patents

Novel pharmaceutical compositions and the uses thereof for controlling the different forms of addiction to drugs Download PDF

Info

Publication number
AU2005300424A1
AU2005300424A1 AU2005300424A AU2005300424A AU2005300424A1 AU 2005300424 A1 AU2005300424 A1 AU 2005300424A1 AU 2005300424 A AU2005300424 A AU 2005300424A AU 2005300424 A AU2005300424 A AU 2005300424A AU 2005300424 A1 AU2005300424 A1 AU 2005300424A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
amisulpride
dopaminergic
combination
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005300424A
Other languages
English (en)
Inventor
Mario Sanchez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trimaran Ltd
Original Assignee
Trimaran Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trimaran Ltd filed Critical Trimaran Ltd
Publication of AU2005300424A1 publication Critical patent/AU2005300424A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2005300424A 2004-11-05 2005-11-07 Novel pharmaceutical compositions and the uses thereof for controlling the different forms of addiction to drugs Abandoned AU2005300424A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0411810A FR2877573B1 (fr) 2004-11-05 2004-11-05 Nouvelles compositions pharmaceutiques et leurs utilisations pour lutter contre les differentes formes d'accoutumance aux drogues
FR0411810 2004-11-05
PCT/FR2005/002775 WO2006048560A2 (fr) 2004-11-05 2005-11-07 Nouvelles compositions pharmaceutiques et leurs utilisations pour lutter contre les differentes formes d'accoutumance aux drogues

Publications (1)

Publication Number Publication Date
AU2005300424A1 true AU2005300424A1 (en) 2006-05-11

Family

ID=34953312

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005300424A Abandoned AU2005300424A1 (en) 2004-11-05 2005-11-07 Novel pharmaceutical compositions and the uses thereof for controlling the different forms of addiction to drugs

Country Status (9)

Country Link
US (1) US20080090895A1 (enExample)
EP (1) EP1814542A2 (enExample)
JP (1) JP2008519016A (enExample)
CN (1) CN101087603A (enExample)
AU (1) AU2005300424A1 (enExample)
CA (1) CA2586277A1 (enExample)
FR (1) FR2877573B1 (enExample)
RU (1) RU2007120707A (enExample)
WO (1) WO2006048560A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1988883A1 (fr) * 2006-02-17 2008-11-12 Trimaran Limited Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
CN118593482A (zh) 2017-12-05 2024-09-06 赛诺维信制药公司 非外消旋混合物及其用途
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4129655A (en) * 1976-04-26 1978-12-12 Ciba-Geigy Corporation Neuroleptic 2-piperidinoalkyl-1,4-benzodioxans
US4412999A (en) * 1982-04-14 1983-11-01 Merck & Co., Inc. Anti-emetic esters of cyproheptadine-3-carboxylic acid and structurally related compounds
US5994392A (en) * 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
WO1997035585A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Anesthetic method
MXPA04007936A (es) * 2002-02-15 2004-11-26 Upjohn Co Compuestos de aril-sustituidos para el tratamiento de enfermedades.

Also Published As

Publication number Publication date
JP2008519016A (ja) 2008-06-05
EP1814542A2 (fr) 2007-08-08
CN101087603A (zh) 2007-12-12
RU2007120707A (ru) 2008-12-10
FR2877573B1 (fr) 2007-02-02
CA2586277A1 (fr) 2006-05-11
WO2006048560A3 (fr) 2006-07-06
WO2006048560A2 (fr) 2006-05-11
FR2877573A1 (fr) 2006-05-12
US20080090895A1 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
Spealman et al. Modulation of the discriminative stimulus effects of cocaine by mu and kappa opioids.
Elliott et al. N-methyl-D-aspartate (NMDA) receptors, mu and kappa opioid tolerance, and perspectives on new analgesic drug development
Herman et al. The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal
Kohl et al. The NMDA receptor complex: a promising target for novel antiepileptic strategies
Han et al. Cholecystokinin octapeptide (CCK-8): antagonism to electroacupuncture analgesia and a possible role in electroacupuncture tolerance
US10517841B1 (en) Compositions and methods for treating respiratory depression with fenfluramine
JP2002522383A (ja) 嗜癖又は嗜癖関連行動の治療
JP2010013477A (ja) ｄ−メタドン、非オピオイド鎮痛剤
JP2005513033A (ja) 麻薬鎮痛剤を増強する方法及び組成物
Dobry et al. Pharmacological characterization of scratching behaviour induced by intracranial injection of substance P and somatostatin
Balerio et al. Baclofen analgesia: involvement of the GABAergic system
CN112218650A (zh) 肽及其用途
Herz et al. Neurochemical aspects of addiction: opioids and other drugs of abuse
US20110039834A1 (en) Novel pharmaceutical compositions for optimizing substitution treatments and extending the pharmacopoeia to global treatment of addictions
CN1382145A (zh) 神经性疼痛治疗剂和神经性疼痛的动物模型
US20080090895A1 (en) Novel Pharmaceutical Composition And Their Uses Thereof For Controlling The Different Forms Of Addiction To Drugs
Kivastik Mechanisms of drug addiction: focus on positive reinforcing properties of morphine
EP3741369A1 (en) Synergistic pharmaceutical combination of the active enantiomer s-ketorolac tromethamine and tramadol chlorhydrate
Badia-Elder et al. Naloxone retards the expression of a genetic predisposition toward alcohol drinking
Bhargava Drugs that modify opioid tolerance, physical dependence, and abstinence symptoms: preclinical and clinical studies
EP1942891B1 (en) Novel combination of drugs as antidepressant
Dow-Edwards et al. Cerebral metabolic interactions between thyroid state and imipramine in the rat.
Dohi et al. Inhibition of Monoamine Neurotransmitter Transporters andCentral Nervous System Stimulation Induced by Synthetic Local Anesthetics and Cocaine: A Comparative Review
Zare et al. Wake-Promoting agents; insights into clinical use and molecular perspectives
Agabio et al. Novel pharmacotherapies and patents for alcohol abuse and alcoholism 1998-2001

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted